Loading...
XLON
CNSL
Market cap5mUSD
Oct 13, Last price  
1.75GBP
Name

Omega Diagnostics Group PLC

Chart & Performance

D1W1MN
XLON:CNSL chart
P/E
P/S
0.55
EPS
Div Yield, %
Shrs. gr., 5y
13.27%
Rev. gr., 5y
-11.05%
Revenues
8m
-11.63%
0003,492,0005,438,0006,199,0007,902,00011,124,00011,262,89811,593,87012,105,31912,743,89614,246,93013,552,7268,756,7569,818,6628,734,8638,539,0007,546,000
Net income
-4m
L+173.95%
-73,000-85,0000238,000221,000187,00031,000527,000582,266692,851739,046571,912713,261-7,269,597974,253-6,828,312-2,104,310-1,409,000-3,860,000
CFO
-3m
L-2.38%
-63,000-78,000311,000600,000170,000322,000673,0001,014,9531,669,1071,247,8931,453,6762,011,324-828,497368,819547,607-2,419,589-3,229,000-3,152,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company operates through two segments, Health and Nutrition, and Global Health and Other. The Health and Nutrition segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Global Health and Other segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment offers VISITECT CD4, an advanced disease rapid test, which is used to treat patients with HIV; and AbC-19, a COVID-19 antibody testing kit, as well as COVID-19 antigen and antibody testing solutions. The company offers its products to hospitals, clinics, laboratories, and healthcare practitioners through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
IPO date
Mar 18, 2004
Employees
91
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT